Lv64
1770 积分 2023-07-03 加入
Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial
2天前
已完结
Proprotein convertase subtilisin/kexin Type 9 inhibitors: past, present, and future
2天前
已完结
PCSK9 (Proprotein convertase subtilisin/kexin type 9) inhibitors: past, present, and the future
2天前
已完结
An Efficient and Reproducible Method for the Isolation and Culture of Primary Cardiomyocytes from Adult Zebrafish
5天前
已完结
The Brussels International Declaration on Lipoprotein(a) Testing and Management
5天前
已完结
Chinese Expert Consensus on the Clinical Diagnosis and Management of Statin Intolerance
5天前
已完结
Short-course hypofractionated proton beam therapy, incorporating 18F-DOPA PET and contrast-enhanced MRI targeting, for patients aged 65 years and older with newly diagnosed glioblastoma: a single-arm phase 2 trial
9天前
已完结
Pharmacological management of elevated LDL in patients with hypercholesterolemia and mixed dyslipidaemia
1个月前
已完结
Resolving Loss of Response to Ustekinumab in Crohn’s Disease: POWER Through or Switch Treatment?
1个月前
已完结
Indirect comparison of statin–ezetimibe and statin–PCSK9 inhibitor combination therapies for coronary artery plaque regression in acute coronary syndrome
1个月前
已完结
皖公网安备34019202002308
